ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.82
+0.31 (+2.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.51
Open14.90
Bid14.25 x 1400
Ask0.00 x 800
Day's Range14.69 - 15.55
52 Week Range2.75 - 16.47
Volume2,120,761
Avg. Volume2,398,501
Market Cap312.331M
Beta (3Y Monthly)5.92
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.08
Trade prices are not sourced from all markets
  • Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?
    Zacks23 hours ago

    Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals, Inc. (ZYNE).

  • Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?
    Simply Wall St.12 days ago

    Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?
    Zacks14 days ago

    Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?

    Is (ZYNE) Outperforming Other Medical Stocks This Year?

  • Associated Press14 days ago

    Zynerba: 1Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire14 days ago

    Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

    DEVON, Pa., May 08, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.

  • Why Zynerba Pharmaceuticals Stock Zoomed Higher Today
    Motley Fool16 days ago

    Why Zynerba Pharmaceuticals Stock Zoomed Higher Today

    The biotech received welcome news from the FDA for lead CBD candidate Zygel.

  • Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy
    American City Business Journals16 days ago

    Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy

    Th FDA awarded the fast track designation to a product the Main Line company is developing to treat patients with Fragile X Syndrome.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia16 days ago

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • GlobeNewswire16 days ago

    Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead development candidate Zygel™ (ZYN002 CBD gel) for treatment of behavioral symptoms associated with Fragile X Syndrome (FXS). FDA’s Fast Track program is designed to facilitate the development of drugs intended to treat serious conditions and fill unmet medical needs, and can lead to expedited review by FDA in order to get new important drugs to the patient earlier.

  • Why Zynerba Pharmaceuticals Stock Is Jumping Today
    Motley Fool22 days ago

    Why Zynerba Pharmaceuticals Stock Is Jumping Today

    An analyst's optimistic outlook provided a spark for the small biotech.

  • What's in the Cards for Zynerba (ZYNE) This Earnings Season?
    Zacks22 days ago

    What's in the Cards for Zynerba (ZYNE) This Earnings Season?

    Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

  • Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
    Zacks28 days ago

    Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

    In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $10.01, marking a +1.11% move from the previous day.

  • Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
    Zackslast month

    Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

    Is (ZYNE) Outperforming Other Medical Stocks This Year?

  • Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
    Zackslast month

    Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $8.23, marking a -0.84% move from the previous day.

  • 5 Marijuana Stocks Wall Street Is Most Bullish On
    Kiplingerlast month

    5 Marijuana Stocks Wall Street Is Most Bullish On

    Cannabis and marijuana stocks are an exciting industry right now. According to Cowen & Co.'s Vivien Azer - a pioneer in cannabis-stock analysis - U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales combined total at least $50 billion. That's on top of an estimated $C12 billion in Canadian revenue by 2025 for both recreational and medical use.The problem? It's still early days for the sector, which means significant risk is involved. It's common to see these primarily small- and mid-cap stocks move 10% or more in response to headlines or quarterly earnings reports. Companies are rushing to establish an early leadership position, and not all of them will end up winners. Plus, the federal legalization of cannabis in the U.S. remains a big question mark.So how do you pinpoint the most compelling investing opportunities in this lucrative industry? One option is to focus on the cannabis stocks that the Street is most bullish on right now.We used TipRanks market data to pinpoint five cannabis and marijuana stocks to buy based on overwhelmingly positive consensus ratings among Wall Street analysts. Let's take a closer look at each. SEE ALSO: Goldman Sachs: 7 Growth Stocks to Buy With Explosive Potential

  • Will Zynerba Pharmaceuticals Continue to Surge Higher?
    Zackslast month

    Will Zynerba Pharmaceuticals Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.

  • ACCESSWIRElast month

    These Four Marijuana Stocks Could Make Moves On Thursday

    CORAL GABLES, FL / ACCESSWIRE / April 11, 2019 / Over the course of the last few years, the marijuana stock market has exploded with excitement after years of societal condemnation since the prohibitionary ...

  • Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • Ladenburg Bullish on Zynerba (ZYNE) Stock as ‘FDA Clarifies Its Views on Availability of Non-Prescription CBD’
    SmarterAnalyst2 months ago

    Ladenburg Bullish on Zynerba (ZYNE) Stock as ‘FDA Clarifies Its Views on Availability of Non-Prescription CBD’

    The FDA has started looking into how it might legalize CBD-laced food products, and this is good news for Zynerba (ZYNE) investors.Today, the agency announced it will hold its first public hearings on CBD, as it weighs rules allowing companies to add the popular cannabis-based compound to food. The hearing will be taking place on May 31. In reaction, Zynerba stock skyrocketed nearly 20% in Tuesday's trading session.Ladenburg analyst Michael Higgins believes "the FDA will be taking further steps in 2019 to remove any non-prescription products being sold that include THC and CBD, while allowing the “…production and marketing of hemp, defined as the plant Cannabis sativa L." This would support the market adoption of Zynerba’s Zygel, a CBD gel treatment for children and adolescents with Fragile X syndrome, the most common form of inherited learning disability and attention deficit disorder.As a result, Higgin reiterates a Buy rating on ZYNE stock, along with a price target of $26, which represents a potential upside of 315% from where the stock is currently trading. (To watch Higgin's track record, click here)Higgin commented, "We believe the removal of current CBD-containing foods, lotions, snacks, oils and other embodiments containing CBD favors the market adoption of Zynerba’s Zygel (CBD gel via a sachet). We have long expected the availability of OTC CBD products during Zygel’s marketing (assuming positive pivotal data in Fragile X patients in 2H’19 and approval in 2H’20), but the stance of the agency suggests less availability of CBD-containing products for which consumers to choose from. From our research, today’s CBDinfused products deliver substantially lower levels of CBD with some containing other active ingredients from the marijuana plant, including THC. We believe this morning's publication reflects the agency’s loss of patience with these products as the number of and marketing of these products have become more ubiquitous and aggressive. While 33 states allow “medical” marijuana the FDA lists marijuana as, “…Schedule I of the CSA (Controlled Substances Act) due to its high potential for abuse, which is attributable in large part to the psychoactive effects of THC, and the absence of a currently accepted medical use for marijuana in the United States” (today’s Fed Reg). In our view, the agency is not relenting, rather, it is leaning on the regulatory statutes several times in this morning's publication."All in all, the legalization of hemp and hemp-based CBD is expected create substantial opportunities for a handful of publicly traded companies, such as Zynerba. Overall, this cannabis stock stands as a 'Strong Buy' name among Wall Street analysts. In the last three months, ZYNE has won 3 bullish 'buy' ratings, with no 'hold' or 'sell' ratings. With a return potential of nearly 220%, the stock's consensus target price stands at $20.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * General Electric (GE) Stock at $14-16 a Share? This Analyst Thinks It’s Possible * Lyft (LYFT) Stock Looks Like It Can Rally Back to $78, Says Analyst * CannTrust (CTST): One Bad Sign for This Cannabis Stock * Lyft (LYFT) Stock Looks Like It Can Rally Back to $78, Says Analyst

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 H.C. Wainwright Global Life Sciences Conference. The presentation will take place on Tuesday, April 9, 2019 at 12:10 PM BST at the Grosvenor House in London, UK. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.

  • ACCESSWIRE2 months ago

    Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT)

    HENDERSON, NV / ACCESSWIRE / March 22, 2019 / Many high-profile companies in the cannabis market have posted incredible gains since start of 2019 and this trend looks to continue. The race to profit from ...

  • ACCESSWIRE2 months ago

    These Four Marijuana Stocks Are Bringing The Heat On Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry. As we look to the future, these smaller companies may play a role in securing potential opportunities for the cannabis industry. ParcelPal Technology Inc (PTNYF) (PKG), Curaleaf Holdings Inc (CURLF) (CURA.CN), Zynerba Pharmaceuticals Inc (ZYNE), and GW Pharmaceuticals plc (GWPH) represent 4 marijuana stocks getting a boost from today's headlines.

  • These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts
    SmarterAnalyst2 months ago

    These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts

    The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued. For example Aurora Cannabis (ACB) - which has doubled year-to-date, is now facing a downside risk of 8% according to the Street. So with that in mind we focused in on stocks that still have massive upside potential ahead. We used TipRanks to focus in on the latest ratings from analysts with the strongest stock picking track record. Without further ado, here are three of the best cannabis stocks to be looking at right now:Aphria Has More Room to RunOver the last three years, Aphria (APHA) shares have exploded by over 850%, and according to the Street significant further upside potential lies ahead.That’s despite a horrendous 2018, which featured a hostile takeover attempt, the exit of its CEO and allegations from a short-seller that insiders profited from acquiring international businesses at highly inflated prices. This was the central accusation of a short report that roiled the stock price, and renewed concerns about the company’s corporate governance.Luckily the most serious allegations have now been refuted. A special board committee found that the price paid for businesses in Latin America was acceptable and that these assets are now progressing according to plan. And with newly-appointed chairman Irwin Simon now acting as CEO, short-seller Quintessential is appeased, tweeting: “With a new management team the company has a chance to a brighter future and we are accordingly moving on to new projects.” Simon is the founder, and former CEO of multi-billion company Hain Celestial Group.In short, this low-cost cannabis producer is ready to rebound. This is reflected by recent ratings from the Street. Most notably, top-rated Clarus analyst Noel Atkinson has just reiterated his buy rating on APHA with a price target of $19.25. This translates into sizeable upside potential of over 85% from the stock’s current share price of $9.63. (To watch Atkinson's track record, click here)According to Atkinson the company needs to stop looking back and start executing to move the ball forward. He believes Aphria’s list of near-term operational milestones is significant, and successful execution could transform the company both in terms of financial results and investor sentiment. “If management can execute, there is the potential for a very substantial re-rating of the stock price from current levels” the analyst tells investors.Overall, Wall Street’s confidence backing this cannabis stock is strong, with TipRanks analytics showcasing APHA as a Strong Buy. Based on 6 analysts polled in the last 3 months, 5 are bullish on Aphria stock, while only 1 remains sidelined. The 12-month average price target stands at $15.33, marking over 50% upside from where the stock is currently trading. (See APHA's price targets and analyst ratings on TipRanks)Zynerba Stock Looks Less FragileZynerba (ZYNE) focuses on transdermal cannabinoid therapeutics. Its goal is to improve the lives of patients affected by rare neuropsychiatric conditions including Fragile X syndrome and autism spectrum disorder. Currently the company is trialing a groundbreaking cannabinoid (CBD) gel. This is the first and only patented permeation-enhanced CBD gel for delivery through the skin and into the circulatory system.According to ZYNE, the gel offers multiple advantages when compared to the more traditional oral delivery. By skipping the digestive process, ZYNE can minimize psychoactive effects, limit drug-drug interaction, and avoid digestion of the drug by the liver.And for investors, now’s the time to start taking a closer look at Zynerba’s investing potential. That’s because this cannabis biotech is gearing up for a transformational 2019 according to five-star HC Wainwright analyst Oren Livnat. Today, Livnat reiterated his buy rating on ZYNE with a $23 price target, which indicates jaw-dropping upside of over 350%. (To watch Livnat's track record, click here)The key data to look out for comes from Zynerba’s lead Fragile X (FXS) program. ZYNE continues to enroll patients for the pivotal Phase 3 study (CONNECT-FX), and the all-important data is expected in 2H19. Livnat is optimistic for positive data, although he admits that this is a risky call given other companies’ failure in this indication.Livnat noted, "We reiterate our Buy, rating and see the current $105M market cap ($27M EV) leaving remarkable upside potential on positive data; as our $23 price target still reflects only a 35% probability of success in FXS.”Overall, this cannabis-related player stands as a 'Strong Buy' name among Wall Street analysts. In the last 12 months, ZYNE stock has won four 'buy' ratings vs. only one 'hold' rating. With a return potential of over 300%, the stock's consensus price target lands at $20. (See ZYNE's price targets and analyst ratings on TipRanks)Arena Stock Falls Under the RadarHere we have a promising biotech that is currently under-the-radar for most investors. Unlike Zynerba, Arena (ARNA) devotes some of its pipeline to CBD therapeutics, while also devoting some of its pipeline to non-cannabinoid medicine.This means that even though its most advanced drug currently in trial is Etrasimod (for colitis, Crohn’s and atopic dermatitis), for cannabis investors Olorinab is the key focus. Also known as APD371, Olorinab is an oral agonist of cannabinoid receptor 2 (CB2), which is part of the natural cannabinoid receptor system found in our bodies. The drug is designed to treat pain associated with gastrointestinal diseases like IBS and Crohn’s- a large and growing market.And the best part is that these drugs could ultimately reduce the need for highly addictive opioid medications. As Bruce Yacyshyn, medical director at UC Health University Hospital, says: “There is a strong clinical need for non-opiate treatments for the management of chronic abdominal pain in patients with gastrointestinal disorders, including Crohn’s disease, ulcerative colitis and irritable bowel syndrome.”As for the timeline, Olorinab Phase 2 trial in IBS pain is expected to begin in 2H19. Cantor Fitzgerald’s Alethia Young is keeping a close eye on these developments, writing “Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim.”She reiterates her buy rating on Arena with a $62 price target- indicating 33% upside potential from current levels. Alongside Young, Needham’s Alan Carr is the only other top analyst who has published a recent rating on Arena. He also rates the stock a Buy, writing “we think olorinab remains an unappreciated potential opportunity with commercial synergies with etrasimod.”To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Is Tesla (TSLA) Stock on Brink After Poor Deliveries Report? * Can iPhone Trade-Ins Help Boost Apple (AAPL) Stock? * Why Tesla (TSLA) Stock Is Headed in the Wrong Direction * This Cannabis Stock Is a Compelling Investment Story

  • PR Newswire2 months ago

    SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

    Phase 3 VANISH program underway, evaluating oral ibrexafungerp for the treatment of acute VVC; anticipate top-line data in the first half of 2020 with NDA submission in the second half of 2020 Oral ibrexafungerp ...